Traynor Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.29M | Buy |
10,205
+372
| +4% | +$120K | 0.23% | 55 |
|
|
2025
Q1 | $2.66M | Buy |
9,833
+483
| +5% | +$130K | 0.22% | 65 |
|
|
2024
Q4 | $2.2M | Buy |
9,350
+2,101
| +29% | +$494K | 0.15% | 73 |
|
|
2024
Q3 | $1.99M | Buy |
+7,249
| New | +$1.99M | 0.12% | 70 |
|
|
2017
Q3 | – | Sell |
-6,479
| Closed | -$516K | – | 169 |
|
|
2017
Q2 | $516K | Buy |
6,479
+1,200
| +23% | +$95.6K | 0.25% | 81 |
|
|
2017
Q1 | $280K | Buy |
+5,279
| New | +$280K | 0.16% | 116 |
|